Catalent (NYSE:CTLT) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Catalent (NYSE:CTLTFree Report) in a research note issued to investors on Wednesday morning. The brokerage issued a sell rating on the stock.

Several other brokerages also recently issued reports on CTLT. Royal Bank of Canada reaffirmed a sector perform rating and issued a $63.50 price target on shares of Catalent in a report on Tuesday, February 20th. Stephens reissued an equal weight rating and set a $63.50 price target on shares of Catalent in a research report on Thursday, April 4th. Finally, UBS Group reiterated a neutral rating and issued a $63.50 price target (up from $58.00) on shares of Catalent in a report on Tuesday, February 6th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, Catalent has an average rating of Hold and an average target price of $53.14.

View Our Latest Stock Report on CTLT

Catalent Trading Up 0.3 %

Shares of Catalent stock opened at $53.79 on Wednesday. The company has a market capitalization of $9.73 billion, a P/E ratio of -8.82, a PEG ratio of 5.75 and a beta of 1.18. Catalent has a 1 year low of $31.80 and a 1 year high of $60.20. The company’s fifty day moving average is $55.83 and its two-hundred day moving average is $51.42. The company has a debt-to-equity ratio of 1.37, a quick ratio of 1.77 and a current ratio of 2.51.

Catalent (NYSE:CTLTGet Free Report) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.21 by ($0.36). Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. The firm had revenue of $1.07 billion for the quarter, compared to analysts’ expectations of $1.11 billion. Analysts forecast that Catalent will post 0.31 earnings per share for the current year.

Institutional Investors Weigh In On Catalent

Institutional investors and hedge funds have recently made changes to their positions in the company. Redwood Grove Capital LLC increased its position in Catalent by 23.0% in the first quarter. Redwood Grove Capital LLC now owns 308,156 shares of the company’s stock worth $17,395,000 after buying an additional 57,600 shares during the period. Swedbank AB acquired a new stake in Catalent during the first quarter valued at approximately $1,659,000. National Wealth Management Group LLC acquired a new position in shares of Catalent in the 1st quarter worth $359,000. California State Teachers Retirement System boosted its holdings in shares of Catalent by 0.4% in the first quarter. California State Teachers Retirement System now owns 284,815 shares of the company’s stock worth $16,078,000 after buying an additional 1,149 shares during the period. Finally, Beryl Capital Management LLC acquired a new position in Catalent during the first quarter valued at $23,756,000.

Catalent Company Profile

(Get Free Report)

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.

Recommended Stories

Analyst Recommendations for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.